Inventories

9 Months Ended

Sep. 30, 2021

INVENTORIESThe Company works closely with third parties to manufacture and package finished goods for sale. Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company’s warehouses. The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.

The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At September 30, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.

The Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory at September 30, 2021 and December 31, 2020. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.

As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition. At September 30, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $9.5 million and $11.7 million, respectively. The Company had $0.2 million and $2.1 million of Vibativ finished goods included in non-current inventory at September 30, 2021 and December 31, 2020, respectively. The Company also has obtained $0.4 million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at September 30, 2021 and December 31, 2020.

At September 30, 2021 and December 31, 2020 the Company's net inventories consisted of the following:


	September 30, 2021		December 31, 2020

Raw materials and work in process	$	13,782,630	$	16,223,162
Consigned inventory	144,583		128,005
Finished goods	5,812,293		5,943,732
Total inventories	19,739,506		22,294,899
less non-current inventories	(9,476,737)		(11,656,742)
Total inventories classified as current	$	10,262,769	$	10,638,157